Date: 2015-02-11
Type of information: Collaboration agreement
Compound: new small-molecule drugs
Company: Pfizer\'s Center for Therapeutic Innovation (USA - NY) Alzheimer\'s Drug Discovery Foundation (USA - NY)
Therapeutic area: Neurodegenerative diseases
Type agreement: collaboration
Action mechanism:
Disease: Alzheimer\'s disease and related dementias
Details: * On February 11, 2015, the Alzheimer\'s Drug Discovery Foundation (ADDF) and Pfizer\'s Centers for Therapeutic Innovation (CTI) announced a collaboration designed to advance the development of new small-molecule drugs for Alzheimer\'s disease and related dementias. As part of the first-of-its kind collaboration in Alzheimer\'s, the ADDF and CTI will jointly invest in translational research projects, with a focus on novel Alzheimer\'s drug targets. The cross-sector alliance is designed to enable project teams, comprised of Pfizer scientists and select academic researchers, to translate novel scientific research into effective therapeutics for Alzheimer\'s disease. The collaboration will allow investigators in Pfizer CTI\'s academic network to apply for joint funding from CTI and the ADDF, with funded projects gaining access to Pfizer CTI\'s unrivaled drug discovery resources and the ADDF\'s expertise in Alzheimer\'s disease research. The first deadline for pre-proposal submissions is February 13, 2015.
Financial terms:
Latest news:
